Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches
Second- or later-line serplulimab-based immunochemotherapy shows promising antitumor activity and survival benefits for SCLC, regardless of prior immunotherapy exposure. Although limited by sample size and retrospective design, these findings highlight the potential of immunotherapy combinations beyond first-line therapy.
Authors
- Shengshu Li
- Qinxiang Guo
- Yanrong Guo (ORCID: https://orcid.org/0000-0001-6949-4879)
- Jianchun Duan (ORCID: https://orcid.org/0000-0003-1479-2304)
- Jinfang Zhai
- Xiaohui Ren (ORCID: https://orcid.org/0000-0001-7376-1191)
- Songyan Han
Institutions
- Shanxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fphar.2025.1591643
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05